|Mr. Michael A. Narachi||Pres, Chief Exec. Officer & Director||1.15M||N/A||1959|
|Dr. Thomas R. Cannell D.V.M.||Exec. VP, COO & Pres of Global Commercial Products||691.11k||N/A||1962|
|Mr. Thomas P. Lynch||Exec. VP, Gen. Counsel, Chief Admin. Officer & Sec.||552.37k||N/A||1967|
|Ms. Monica Forbes||VP & Acting CFO||N/A||N/A||1976|
|Mr. Stephen A. Moglia||Chief Accounting Officer, VP and Controller||N/A||N/A||1965|
Orexigen Therapeutics, Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products primarily in the United States, Europe, and South Korea. It offers Contrave for the treatment of obesity. The company also offers Contrave under the Mysimba brand name. Orexigen Therapeutics, Inc. was founded in 2002 and is headquartered in La Jolla, California. On March 12, 2018, Orexigen Therapeutics, Inc., filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
Orexigen Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.